Late-breaking MEMBRANE analysis highlights vascular penetration in middle meningeal artery embolization for patients with chronic subdural hematoma
CEREGLIDE™ 92 and the aspiration portfolio to be featured in presentations and lunch symposium focused on ischemic stroke
ORLANDO, Fla., Nov. 20, 2025 – Johnson & Johnson, a global leader in neurovascular care, today announced its scientific program for the 2025 Society of Vascular and Interventional Neurology (SVIN) Annual Meeting, taking place Nov. 19–22 in Orlando, Florida. Presentations will feature new data in chronic subdural hematoma (cSDH) and acute ischemic stroke, including a late-breaking post-hoc analysis from the MEMBRANE study, a meta-analysis of randomized controlled trials on middle meningeal artery embolization (MMAe), and new research on access approaches and aspiration technique variation.
“This year’s SVIN meeting represents an important opportunity to bring forward new evidence in both the treatment of chronic subdural hematoma and ischemic stroke, two areas where Johnson & Johnson Neurovascular is committed to advancing new treatment options,” said Christian Cuzick, Worldwide President, Johnson & Johnson MedTech Neurovascular. “With a robust scientific schedule, we’re proud to share new data on CEREGLIDE™ 92 and cyclic aspiration as we continue developing technologies that support physicians in achieving more effective outcomes for their patients.”
Johnson & Johnson MedTech Neurovascular scientific presentations at SVIN include:
Chronic Subdural Hematoma
- MEMBRANE Post-Hoc Analysis: Vascular Penetration in Middle Meningeal Artery Embolization (MMAE) for Chronic Subdural Hematoma
H. Shoirah | Nov. 22, 1–1:10 p.m. | Late-breaking Oral Presentation | View abstract
- Middle Meningeal Artery Embolization for the Treatment of Chronic Subdural Hematoma: A Meta-analysis of Randomized Controlled Trials
M. Mirza | Nov. 20, 6–7 p.m. | Moderated Poster Presentation | View abstract
- Treatment Trends Among Patients With Newly Diagnosed Chronic Subdural Hematoma: A US Database Population Analysis
E. Kottenmeier | Nov. 21, 8 a.m.–5 p.m. | Printed Poster Abstract | View abstract
Ischemic Stroke
- A Comparative Analysis of Pre-clinical and Clinical Outcomes for Cyclic and Standard Thrombo-aspiration Techniques in Acute Ischemic Stroke
N. Moreton | Nov. 21, 8 a.m.–5 p.m. | Printed Poster Abstract | View abstract
- Cyclic vs. Standard Aspiration Techniques for Thrombo-aspiration in Acute Ischemic Stroke: A Comparative Analysis of Pre-clinical Outcomes
N. Moreton | Nov. 21, 8 a.m.–5 p.m. | Printed Poster Abstract | View abstract
- Transradial Versus Transfemoral Access in Mechanical Thrombectomy for the Treatment of Acute Ischemic Stroke
M.M. Perez | Nov. 21, 8 a.m.–5 p.m. | Printed Poster Abstract | View abstract
- Procedural Variations and Failure Rates in Transradial vs. Transfemoral Access for Acute Ischemic Stroke Thrombectomy
M.M. Perez | Nov. 22, 11 a.m.–noon | Moderated Poster Presentation | View abstract
Migraine & Aneurysm
- Impact of Prophylactic Intervention on Migraine Burden: Effect on Headache Days, Migraine Days, MIDAS, and 50% Responder Rates versus Placebo
P. Guastavino | ePoster | View abstract
- Outcomes Associated With The Enterprise Stent Treating Ruptured Intracranial Aneurysms: A Systematic Literature Review
E. Kottenmeier | ePoster | View abstract
Cardiovascular Solutions from Johnson & Johnson MedTech
Across Johnson & Johnson, we are tackling the world’s most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation we are addressing conditions with significant unmet needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation. We are the global leaders in heart recovery, circulatory restoration and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke. For more information, visit here and connect on LinkedIn and X
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in cardiovascular, orthopedics, surgery and vision solutions at thenext.jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to the Impella Platform. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
© Johnson & Johnson and its affiliates 2025. All rights reserved. US_NEU_ISCH_409178
Media contact:
James Alley
[email protected]